MindRank Pharma Successfully Holds National Investigator Meeting for Phase IIb Clinical Trial of Oral Small Molecule GLP-1RA MDR-001

The Phase IIb clinical trial being advanced this time isA Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Long-term Administration of Oral Small Molecule MDR-001 Tablets in Overweight or Obese Subjects.The study has enrolled over 300 subjects, with Peking University People's Hospital as the leading unit. Professor Li-Nong Ji, as the principal investigator, is leading researchers from 19 centers across China in this research.

Professor Linong Ji from Peking University People's Hospital delivered the opening speech at the investigator meeting.Professor Ji stated that the global GLP-1 drug development is currently in an active phase, and the AI-powered small molecule oral GLP-1RA project MDR-001 by MindRank has entered Phase IIb clinical research. It is hoped that experts from various centers can gain a deeper understanding through this conference.「MindRank」And the MDR-001 product, congratulating the project on its completion of initiation within one month and enrollment of 317 subjects within 1.5 months, while expressing high anticipation for the commencement of the Phase III clinical trial of the MDR-001 project.

Mr. Niu Zhangming, Founder and CEO of "MindRank"Delivered an online speech to congratulate the conference on its successful convening, while expressing gratitude to all experts for their participation both offline and online. MDR-001 is the first innovative drug developed by MindRank to advance to Phase IIb clinical trials, utilizing the self-developed AI pharmaceutical platform Molecule Pro.^™Efficiently completed AI-customized precision drug design and virtual screening of molecular structures, with lower synthesis costs, superior weight-loss efficacy, and safety. We look forward to collaborating closely with researchers worldwide to bring this innovative therapy to a broad global patient population more quickly.

Dr. Long Zhang, Co-founder and President of China Region at MindRankShared the company's R&D pipeline in the fields of metabolism and oncology, as well as the development of the molecular glue platform, with a particular focus on the MDR-001 project. As a β-arrestin 2 highly selective GLP-1 receptor agonist, MDR-001 not only retains the islet cell repair and protection functions brought by β-arrestin recruitment but also avoids the restricted insulin secretion and mediated endocytosis desensitization caused by β-arrestin 1 recruitment. In early clinical studies, the MDR-001 project has shown significant weight loss efficacy along with several potential differentiating advantages.

Ms. Lixia Dong, Medical Director of "MindRank"Presented detailed safety and efficacy data from the Phase I/IIa clinical trial of the MDR-001 project, along with an in-depth interpretation of the design and specific execution of its Phase IIb protocol. The attending experts engaged in thorough discussions on protocol details, key focuses for the next stage of research, and participant management. They also shared and exchanged valuable experiences accumulated during the trial process, expressing their commitment to unite all forces to ensure the high-quality completion of the project.

Mr. Hu Tianxin, Senior Director of Clinical Operations at MindRankIt was noted that clinical trials for weight loss are extremely complex. We need to be investigator-led, patient-centered, and scientifically rigorous, respecting and uniting all partners. We must anticipate potential difficulties in advance while boldly attempting solutions and carefully verifying them to seek the optimal solution. This will promote the smooth progress of the MDR-001 Phase IIb clinical trial and lay a solid foundation for entering Phase III clinical research.

At the end of the conference, Professor Ji Linong gave a comprehensive summary of the discussions, and Dr. Zhang Long, representing MindRank, once again expressed heartfelt gratitude to researchers across China.We look forward to all parties jointly promoting the high-quality and efficient completion of the MDR-001 multi-center Phase IIb clinical study in China, so that more patients around the world can benefit as soon as possible.

MDR-001 is MindRank's self-developed Molecule Pro^™Innovative Drug Pipeline Designed with the Aid of a One-Stop AI Drug Discovery Platform. After 12 weeks of treatment with MDR-001 tablets, the average weight loss in the MDR-001 group was 9.0% (vs. 2.1% in the placebo group), with an adjusted average weight loss of 6.9% after placebo correction. Among the participants, 87.5% experienced a weight reduction of more than 5%. Meanwhile, MDR-001 demonstrated good safety and tolerability, with no serious adverse events reported, no participant withdrawals due to adverse events, and the maximum tolerated dose far from being reached. The most common treatment-related adverse events were mild to moderate gastrointestinal reactions. The MDR-001 project is currently undergoing Phase IIb clinical trials.

MindRank is a clinical-stage AI-driven innovative drug discovery company. The company’s vision is to continuously deliver differentiated and high-clinical-value drug candidates by promoting the integration of various cutting-edge technologies in artificial intelligence and new drug development, thereby helping more lives regain health.

The AI pharmaceutical solution of the company was rated as one of the "11 most important AI drug R&D breakthrough achievements globally from 2018 to 2020" by the authoritative European and American institution Deep Pharma Intelligence. In 2023, it was included in Forbes' "Forbes Asia 100 to Watch" list, with only 11 startups from mainland China making the list. In 2024, it was selected for Fortune magazine's IMPACT Enterprise List as one of "China's most socially influential entrepreneurial companies."

For more information, please visit the website: www.mindrank.ai

Cooperation: bd@mindrank.ai

Other: info@mindrank.ai